MicroRNA-based drug development comapny Rosetta Genomics Ltd. (Nasdaq:ROSG) today published its financial report for the second quarter of 2007. Like many biomedical companies, it did not record any sales; the financials focused on progress in the company’s R&D, contracts with third parties, and the time for products to reach market.
In a separate development this week, Rosetta signed collaboration agreement with Ben Gurion University of the Negev, for the development of microRNA-based therapeutic applications for several key viruses including the Epstein-Barr virus (EBV) and Herpes Simplex Viruses (HSV) read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment